HCWB:NASDAQ, HCW Biologics Inc.
HCWB stock overview
HCW Biologics Inc. (HCWB:NASDAQ) closed at $0.800 on November 16, 2026,
up 3.48% on the day.
The stock trades 96.7% below its 52-week high of $23.94
and 7.7% above its 52-week low of $0.743.
Over the past year, it lost 94.5%.
HCW Biologics Inc. is part of the Health Care sector.
Key figures
- Price
- $0.800
- Day change
- +3.48%
- Volume
- 87,029
- Average volume
- 401,128
- Market cap
- 1M+
- 52-week range
- $0.743 – $23.94
- 50-day average
- $1.52
- 200-day average
- $3.78
Price action over the past year
In 252 trading sessions since November 14, 2025, HCWB closed higher on 82 days (33%).
Its best day was May 15, 2026 (+262.02%) and its worst was March 23, 2026 (-29.91%).
The stock moved 10% or more in a single session 44 times.
It opened at least 5% above the previous day's high 4 times.
Recent signals
HCWB news
-
Nov 16, 2026:
HCW Biologics Reports Third Quarter 2026 Business and Clinical Development Highlights and Financial Results
-
Nov 6, 2026:
HCW Biologics' Presentation for HCW11-040 Recognized for Scientific Rigor, Novelty, Clarity and Potential Impact on Cancer Immunotherapy by the Society for Immunotherapy of Cancer
-
Nov 6, 2026:
HCW Biologics Presents Newly Identified Distinctive Features of Its Lead T Cell Engager Candidate Built with Company's Proprietary T-Cell Engager Platform, Further Supporting Its Use in Treating Solid Tumors at the Society for Immunotherapy of Cancer's 41st Annual Meeting
-
Nov 5, 2026:
HCW Biologics Secures up to $10.0 Million in Cash Through Debt Financing
-
Oct 9, 2026:
HCW Biologics Maintains Momentum Toward Completion of IND Application for Clinical Study to Evaluate Lead T-Cell Engager in Solid Tumors
-
Sep 24, 2026:
HCW Biologics Announces Pricing of $1.5 Million Private Placement
-
Sep 8, 2026:
HCW Biologics Signs Akron Biotech Distribution Deal for CAR-T Manufacturing Reagent
-
Sep 8, 2026:
HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T Cells
About HCW Biologics Inc.
HCW Biologics Inc is a preclinical stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between chronic, low-grade inflammation and age-related diseases. It is developing HCW9218 as an injectable immunotherapeutic for patients with solid tumors.
Similar stocks
Find more stocks like HCWB with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.